ConductScience.org, home

Comparison · NCT01610414-af2b2bda

GSK1437173A Group vs Placebo Group: Number of Subjects With Confirmed HZ-associated Complications

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. GSK1437173A Group vs Placebo Group: Number of Subjects With Confirmed HZ-associated Complications. Trial comparisons, record NCT01610414-af2b2bda. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01610414-af2b2bda

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.003450.001170.0101wilson
Risk in group 20.01530.008950.026wilson
Risk difference, group 1 minus group 2-0.0118-0.0228-0.00266newcombe hybrid score
Risk ratio, group 1 over group 20.2260.06460.789log
Odds ratio, group 1 over group 20.2230.06330.786log
Number needed to treat, for one fewer participant with the outcome on GSK1437173A Group than on Placebo Group84.544377from the risk difference interval

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1GSK1437173A GroupSubjects received 2 doses of the candidate HZ vaccine GSK1437173A, administered intramuscularly (IM) in deltoid region of the non-dominant arm, according to a 0, 1-2-Months schedule.3870OG000
Group 2Placebo GroupSubjects received 2 doses of placebo (saline solution), administered intramuscularly (IM) in deltoid region of the non-dominant arm, according to a 0, 1-2-Months schedule.13851OG001

Outcome

Type
SECONDARY
Title
Number of Subjects With Confirmed HZ-associated Complications
Description
This analysis excluded complications that were linked to a confirmed HZ case that occurred after the start of the relapse treatment.
Time frame
From Month 0 until the cut-off date for final analysis (median follow-up was of 21 months)
Population
The analysis was performed on the modified Total Vaccinated Cohort, which excluded subjects from the Total Vaccinated Cohort analysis who were not administered with the second vaccination or who received vaccine doses/or replacement not on the same group or who developed a confirmed case of HZ prior to 1 month after the second vaccination.

Source ClinicalTrials.gov

Trial

Title
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
NCT number
NCT01610414
Phases
PHASE3
Conditions
Herpes Zoster
Interventions
Herpes Zoster vaccine GSK1437173A, Placebo
Lead sponsor
GlaxoSmithKline
Results first posted
2018-01-23

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01610414-af2b2bda